Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;62(9):1170–1176. doi: 10.1002/jcph.2056

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Coverage of estimated CSF C_ss,avg over ALK inhibition targets in patients receiving 100 mg QD lorlatinib dosing. The blue line indicates the unbound (free) target concentration for the inhibition of wild‐type ALK (2.58 ng/mL). The green line indicates the unbound (free) target concentration for the inhibition of L1196M (21.08 ng/mL). The red line indicates the unbound (free) target concentration for the inhibition of G1202R (67.06 ng/mL). ²⁹ ALK, anaplastic lymphoma kinase; CSF, cerebrospinal fluid; C_ss,avg, average steady‐state plasma concentration; QD, once daily.